Digital Diagnostics vs Magentiq Eye (2026)
Two cleared devices that both remove a dependency on specialist availability, at different levels of autonomy. Digital Diagnostics issues a diabetic retinopathy result with no physician reading the image, under the authorization that created autonomous diagnosis in the United States in 2018, backed by a pivotal trial run in primary care with equity built into its design. Magentiq assists an endoscopist who is present throughout, running inference locally between the scope and the monitor so video never leaves the room, with authorization in three jurisdictions and an international multicenter trial behind it. The evidence bar scales with autonomy: a system that decides alone needs pivotal evidence in the population it will serve, and one that assists needs to show the clinician does better with it.
- It issues a diagnosis with no clinician reading the image, under the authorization that created the category in 2018.
- Equity was an input to its pivotal trial design rather than a disclosure added afterward.
- A reimbursement pathway exists for the workflow, which decides whether a primary care clinic runs the test at all.
- The device performs local inference between the scope and the monitor in real time, so no video leaves the procedure room.
- It holds authorization in three jurisdictions, maintained across product versions.
- An international multicenter trial stands behind it, which addresses the variation that matters most in this procedure.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Digital Diagnostics and Magentiq Eye are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Digital Diagnostics | Magentiq Eye |
|---|---|---|
| Primary category | Diagnostics & Genomics | Radiology & Imaging AI |
| Founded | 2010 | 2014 |
| Headquarters | Coralville, Iowa, United States | Haifa, Israel |
| Website | digitaldiagnostics.com | magentiq.com |
Side by Side
Select any grade to read the note behind it.
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
Digital Diagnostics, founded in Coralville, Iowa as IDx Technologies by retina specialist and computer engineer Michael Abramoff, MD, PhD, builds autonomous AI diagnostic systems. Its flagship, LumineticsCore (cleared as IDx-DR), detects more than mild diabetic retinopathy including macular edema from retinal images and returns a result at the point of care without physician interpretation of the image: refer to an eye care professional, rescreen in 12 months, or insufficient image quality.
Source: AI Health Index, September 2026
Magentiq Eye is a Haifa company founded in 2014 by Dror Zur that builds real time computer aided detection for colonoscopy. Its product, MAGENTIQ-COLO (registered with the FDA as the ME-APDS automatic polyp detection system), takes the video feed from the colonoscope, analyzes each frame with a deep learning model during the procedure, and returns the video to the monitor with suspected polyps marked, so the endoscopist walks past fewer adenomas.
Source: AI Health Index, September 2026
Questions buyers ask
How do Digital Diagnostics and Magentiq Eye work with the EHR?
For Digital Diagnostics, the regulatory record for the current versions describes DICOM image submission, and results reach the provider through the company's systems, including SphereDx, which it lists as a diagnostic results platform.
With Magentiq Eye, the device sits between the colonoscope and the display and preserves the existing procedure workflow, so adoption needs no record system project and no interface build; the company's partnership with PENTAX Medical suggests hardware compatibility with that maker's endoscopes, which is not the same as record integration. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
How do Digital Diagnostics and Magentiq Eye handle patient data?
In Digital Diagnostics' case, the 2022 clearance summary (K213037) shows the path the data takes: client software sends images to analysis on dedicated servers hosted in a secure datacenter, so images leave the site.
For Magentiq Eye, the 510(k) summary describes the device acquiring the endoscope's video and processing it in real time in a unit that sits in the video path of the procedure room, with the highlighted video shown on local monitors. It does not say whether video is stored on the unit, whether recordings are transmitted after the procedure, for how long anything is retained, or whether recorded procedures are used to improve the model. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
Which settings and specialties do Digital Diagnostics and Magentiq Eye cover?
With Digital Diagnostics, the pivotal trial ran prospectively at primary care sites, so the setting of use is the setting validated. Pediatric evidence exists (the SEE study) and is outside the authorized indication.
In Magentiq Eye's case, coverage is white light screening and surveillance colonoscopy in gastroenterology (K223473), deployed in hospital endoscopy units and ambulatory centers across the US, Europe and Israel, with a PENTAX Medical partnership covering EMEA, JAPAC, Latin America and North America. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
What evidence is published for Digital Diagnostics and Magentiq Eye?
For Digital Diagnostics, the SEE study (Diabetes Care, 2021) extended safety, efficacy and equity testing to a youth population outside the authorized indication. A review in Ophthalmology Science assessed LumineticsCore alongside EyeArt and AEYE Diagnostic Screening and gathered implementation experience from academic health systems, which places the product in a third party comparison.
With Magentiq Eye, the international trial ran for fourteen months across ten centers in Europe, the United States and Israel, with 31 endoscopists and about 950 randomized patients, was registered in advance, and was published in Lancet Digital Health in February 2024; the 510(k) summary (K223473) reports its results. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Radiology & Imaging AI page.
Both are cleared devices operating at the point of care and both remove a dependency on specialist availability, but the autonomy differs: one issues a diagnosis with no clinician reading the image, the other assists an endoscopist who is present throughout. The evidence demanded should differ accordingly. Digital Diagnostics publishes a Notice of Privacy Practices for its exams but no security attestation. Magentiq publishes no health privacy statement or business associate terms, though its local inference architecture removes much of what those would govern. Neither publishes pricing.